InGeneron Announces Publication of Rotator Cuff Feasibility Study

FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron’s Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function Over Corticosteroid Injection to Address Symptomatic Partial-Thickness Rotator Cuff Tears InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose ® RT System in the Journal of Orthopaedic Surgery and Research . Houston, TX, April 7, 2020 – Results of a U.S. FDA-approved, randomized controlled feasibility study on treatment of symptomatic partial-thickness rotator cuff tears (sPTRCT) with fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) are now available in the Journal of Orthopaedic Surgery and Research . This prospective multicenter feasibility study performed by Sanford Health is the first randomized controlled trial in which cells isolated from patients’ own adipose tissue were compared to another therapy option for treating sPTRCT. Specifically, subacromial injection of corticosteroid was compared to injection of UA-ADRCs isolated from the subjects’ own adipose tissue using InGeneron’s Transpose ® RT System. Assessment at 24 and 52 weeks post-treatment demonstrated significantly higher mean American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) total scores (indicating reduced pain and improved shoulder function) of the subjects in the UA-ADRC group compared to the subjects in the corticosteroid group at both time points. Additionally, there were no significant complications or adverse events associated with the injection of UA-ADRCs during a period of twelve months post-treatment, with 20% of the subjects in the corticosteroid group experiencing full-thickness rotator cuff tears during the same period post-treatment. Based on the positive outcome of this feasibility study, InGeneron is currently enrolling a multi-centre (up to 20 sites), nationwide FDA IDE pivotal study involving a significantly larger number of patients than the feasibility study (ClinicalTrials.gov Identifier: NCT03752827 ). Symptomatic partial-thickness rotator cuff tears (sPTRCT) are among the most common injuries and ailments of the shoulder, especially in elderly patients. Subacromial corticosteroid injection, one of the standard therapies for sPTRCT, often leads to a temporary improvement in clinical symptoms, but not a cure. Furthermore, repeated subacromial corticosteroid injections were reported to be detrimental to tendon healing. “The study shows that unmodified, autologous ADRCs isolated from patients’ own adipose tissue at point-of-care using InGeneron’s Transpose ® RT System represent a powerful and highly innovative alternative for treating symptomatic PTRCT,” said Dr. John Furia, a board-certified orthopaedic surgeon, who along with Dr. Nicola Maffulli (London, UK) served as clinical and scientific advisors. “Injection of ADRCs into diseased tendons has the potential to jump-start the human response. The science is catching up with the hype and I’m optimistic this modality will play an important role in how we treat our patients going forward.” The complete results of the study, entitled “Safety and efficacy of treating symptomatic, partial-thickness rotator cuff tears with fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) isolated at the point of care: a prospective, randomized, controlled first-in-human pilot study“, (DOI: https://doi.org/10.1186/s13018-020-01631-8 ) were published in the Journal of Orthopaedic Surgery and Research on March 30, 2020. About the Transpose ® RT System and FDA approved clinical trials InGeneron’s Transpose ® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase ® , a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients’ own adipose tissue at point-of-care in less than 90 minutes for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance. The Transpose® RT System is being investigated in several FDA-approved clinical trials and is currently available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at www.clinicaltrials.gov under the identifiers NCT03752827 , NCT03513731 , and NCT03503305 . About InGeneron InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA. www.ingeneron.com Contact: InGeneron, Inc. Eckhard Alt, MD, PhD Executive Chairman of InGeneron +1 (713) 440 9900 [email protected] Media Inquiries Jon Stone Stone Communications Consulting +1 (612) 475 5955 [email protected] Recent Posts Press Releases Feb 4, 2026 InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices Press Releases Jul 23, 2025 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System Press Releases Nov 13, 2023 InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears Press Releases Nov 3, 2023 InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial Press Releases Jan 6, 2023 New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups Press Releases Jan 24, 2022 InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics Press Releases Jan 6, 2022 American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears News Nov 23, 2021 InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body Press Releases Jul 23, 2021 InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment Press Releases Apr 7, 2020 InGeneron Announces Publication of Rotator Cuff Feasibility Study Press Releases Oct 31, 2019 InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure News Jun 11, 2019 InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic Press Releases May 15, 2019 InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy Press Releases Mar 21, 2019 InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration News Jan 23, 2019 InGeneron Expands Development Pipeline with Two Osteoarthritis Programs News Dec 12, 2018 InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy News Sep 18, 2017 InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology News Mar 6, 2017 InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies News Dec 5, 2016 InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences News Nov 21, 2016 InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS Have any Questions ? Important In the US InGeneron’s Transpose ® RT cell therapy platform is for investigational use only. By Clicking ‘Continue’ I confirm acknowledgment Continue Our mission is to enable novel, safe, and evidence-based therapies by unlocking the healing potential of each patient’s own regenerative cells. Twitter Linkedin Facebook 2 Youtube InGeneron, Inc. 8205 El Rio St Houston, TX 77054 USA +1 (713) 440 9900 [email protected] Subscribe to our Newsletter © 2026 by InGeneron, Inc. Site info . All rights reserved. Web Design & Development by BelugaLab Privacy Policy

The release as fetched from its publisher. ingeneron.com ↗